PACIRA PHARMACEUTICALS INC's ticker is PCRX and the CUSIP is 695127100. A total of 254 filers reported holding PACIRA PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 0.88 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $50,987,000 | +75.1% | 1,661,913 | +128.7% | 0.06% | +93.9% |
Q2 2023 | $29,117,000 | -42.3% | 726,658 | -41.2% | 0.03% | -45.0% |
Q1 2023 | $50,421,000 | -35.9% | 1,235,498 | -39.3% | 0.06% | -35.5% |
Q4 2022 | $78,650,000 | -49.6% | 2,037,049 | -30.6% | 0.09% | -51.3% |
Q3 2022 | $156,083,000 | -24.9% | 2,933,798 | -17.7% | 0.19% | -18.0% |
Q2 2022 | $207,776,000 | -33.0% | 3,563,907 | -12.3% | 0.23% | -1.3% |
Q1 2022 | $309,997,000 | +36.5% | 4,061,812 | +7.6% | 0.24% | +24.9% |
Q4 2021 | $227,160,000 | +10.1% | 3,775,303 | +2.4% | 0.19% | +7.4% |
Q3 2021 | $206,402,000 | -8.4% | 3,685,754 | -0.8% | 0.18% | -4.9% |
Q2 2021 | $225,442,000 | -2.3% | 3,715,264 | +12.9% | 0.18% | -43.3% |
Q1 2021 | $230,745,000 | +40.0% | 3,292,131 | +19.5% | 0.33% | +35.3% |
Q4 2020 | $164,801,000 | +12.1% | 2,754,028 | +12.6% | 0.24% | -3.2% |
Q3 2020 | $147,058,000 | +38.4% | 2,446,086 | +20.7% | 0.25% | +36.1% |
Q2 2020 | $106,293,000 | +85.7% | 2,025,772 | +18.7% | 0.18% | +55.1% |
Q1 2020 | $57,246,000 | -39.0% | 1,707,308 | -17.6% | 0.12% | -11.9% |
Q4 2019 | $93,869,000 | +37.3% | 2,072,174 | +15.4% | 0.13% | +16.5% |
Q3 2019 | $68,368,000 | -72.6% | 1,795,855 | -68.7% | 0.12% | -19.0% |
Q2 2019 | $249,237,000 | +262.6% | 5,730,882 | +217.3% | 0.14% | +21.4% |
Q1 2019 | $68,731,000 | -25.2% | 1,805,866 | -15.5% | 0.12% | -34.3% |
Q4 2018 | $91,905,000 | -23.8% | 2,136,332 | -12.9% | 0.18% | -9.2% |
Q3 2018 | $120,609,000 | +62.1% | 2,453,888 | +5.7% | 0.20% | +53.1% |
Q2 2018 | $74,392,000 | +53.8% | 2,321,125 | +49.4% | 0.13% | +45.5% |
Q1 2018 | $48,380,000 | -16.3% | 1,553,114 | +22.6% | 0.09% | -13.7% |
Q4 2017 | $57,812,000 | +33.4% | 1,266,414 | +9.7% | 0.10% | +30.8% |
Q3 2017 | $43,353,000 | -16.7% | 1,154,545 | +5.8% | 0.08% | -17.9% |
Q2 2017 | $52,066,000 | +6.2% | 1,091,530 | +1.6% | 0.10% | +6.7% |
Q1 2017 | $49,010,000 | +50.6% | 1,074,770 | +6.7% | 0.09% | +43.5% |
Q4 2016 | $32,541,000 | -17.1% | 1,007,449 | -12.2% | 0.06% | -18.4% |
Q3 2016 | $39,270,000 | +785.7% | 1,147,579 | +772.8% | 0.08% | +1800.0% |
Q2 2016 | $4,434,000 | +5.4% | 131,476 | +65.6% | 0.00% | -50.0% |
Q1 2016 | $4,206,000 | +114.7% | 79,390 | +272.2% | 0.01% | +100.0% |
Q2 2014 | $1,959,000 | +71.2% | 21,329 | +30.5% | 0.00% | +100.0% |
Q1 2014 | $1,144,000 | -20.3% | 16,340 | -34.6% | 0.00% | -33.3% |
Q4 2013 | $1,436,000 | +35.3% | 24,981 | +13.2% | 0.00% | +50.0% |
Q3 2013 | $1,061,000 | – | 22,071 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Gagnon Advisors, LLC | 251,140 | $19,167,000 | 8.83% |
GAGNON SECURITIES LLC | 610,933 | $46,626,000 | 7.60% |
Tamarack Advisers, LP | 205,000 | $15,646,000 | 7.40% |
Spyglass Capital Management LLC | 1,871,040 | $142,798,000 | 4.88% |
Lisanti Capital Growth, LLC | 302,413 | $23,080,000 | 2.59% |
Rock Springs Capital Management LP | 1,000,000 | $76,320,000 | 1.92% |
MESIROW FINANCIAL INVESTMENT MANAGEMENT - Fixed Income | 208,197 | $15,890,000 | 1.76% |
JABODON PT CO | 49,052 | $3,744,000 | 1.70% |
Zweig-DiMenna Associates LLC | 166,675 | $12,721,000 | 1.70% |
NEUMEIER POMA INVESTMENT COUNSEL LLC | 317,425 | $24,226,000 | 1.63% |